BCL2L1 Polyclonal Antibody

Product Specifications

Background

Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Isoform Bcl-X (L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F (1) F () activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. Isoform Bcl-X (S) promotes apoptosis.

Synonyms

BCLX; BCL2L; BCLXL; BCLXS; Bcl-X; bcl-xL; bcl-xS; PPP1R52; BCL-XL/S; Bcl-2-like protein 1; Bcl2-L-1; Apoptosis regulator Bcl-X; BCL2L1

Gene ID

598

Swiss Prot

Q07817

Cellular Locus

Cytoplasm, Nucleus, Cell membrane

Host

Rabbit

Cross Reactivity

Human, Mouse

Immunogen

81-200/233

Target

BCL2L1

Clonality

Polyclonal

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human BCL2L1

Applications

WB, ELISA, FCM, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1ug/ul

Dilution

WB (1:300-5000), ELISA (1:500-1000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)